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and mesenchymal stem cell markers (CD44 (Hermes antigen,
hyaluronan receptor), CD90 (Thy-1), cadherin-11 showed in-
creased expression levels. Both mixed and puriﬁed synovial cells
were negative for markers of haematopoeetic progenitors (CD34)
and further developmental stages of blood cells (CD11b, CD45)
(Fig. 1).
The chondrogenic differentiation and proliferative potential of
MSCP and SFB cells were compared using biochemical and
histological analyses (Fig. 2).
Figure 2. Comparison of the proliferative and chondrogenic potential of mixed
synovial cell population (MSCP) with the puriﬁed type-B synovial ﬁbroblasts
(SFB) cultivated for 7 days with 20 ng/ml TGF-β1. (a) DNA and (b) GAG per
pellet, (c) histological cross-sections of MSCP-pellets and SFB-pellets depicting
staining for GAG (Safranin-O/Fast Green) and type II collagen (immunohisto-
chemistry) – Scale bars are 200 μm. (d) Relative mRNA expression of aggre-
can, type II collagen, and type I collagen genes in the SFB-pellets with respect to
those in the MSCP-pellets. Data presented as mean ± SD, *p<0.05, **p<0.01,
n=3.
Conclusions: We have demonstrated the cells from mammalian
synovium contain a mesenchymal stem cell population capable of
chondrogenic differentiation and that the CD14-negative isolation
yields an enhanced cell population (SFB) that is more potent than
MSCP as a cell source for cartilage tissue engineering.
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Purpose: Cartilage injuries are a common clinical problem and as
this tissue possesses limited self-renewal potential, any damage to
this tissue, such as those arising from sports injuries, osteoarthritis
and rheumatoid arthritis will eventually result in loss of cartilage
with possible exposure of the subchondral bone and resultant pain
and immobility.
The World Health Organisation (WHO) has shown that the burden
to society of these disorders is not only signiﬁcant in terms
of absolute disability-adjusted-life years (DALYs) but that it is
seen (and is growing) in both the developed and developing
world. Strategies for the assisted repair of skeletal tissues are
urgently required to alleviate the high morbidity associated with
joint disorders.
Current therapies are restricted by shortage of grafting material,
insufﬁcient biocompatibility of the implanted material and absence
of cells with reparative potential. The unique biological properties
of human embryonic stem cells (hESCs) highlight them as ideal
candidate cell sources for such therapies by virtue of their directed
differentiation potential and their ability to undertake large scale
proliferation for bulking up prior to use.
The aim of this study was to produce hESC-derived chondropro-
genitor cells and to investigate their potential to repair an articular
cartilage defect in the rat knee.
Methods: Cells from a registered hESC line were expanded in
feeder free conditions using established techniques. Embryoid
body-derived cells were cultured using an in-house deﬁned me-
dia system capable of inducting chondrogenic differentiation to
form 3D cell constructs. Markers of chondrogenic differentiation
were monitored in constructs prior to use experimentally. Pre-
labeling with the ﬂuorescent cellular probe CM-Dil (20μM; Molec-
ular Probes™) allowed tracking of implanted human cells in the
rat defect. Defects were created surgically on the femoropatellar
groove of the knee joint of rats and the constructs were implanted.
Empty defects served as controls.
Samples were collected 21 days post-implantation and snap
frozen. Fixed cryosections were assessed both morphologically
and histologically for repair and to track the persistence of im-
planted human cells. A subset of constructs were collected at
the time of implantation to enable characterisation of implanted
material.
Results: HESC-derived constructs exhibited a chondrogenic phe-
notype at the time of implantation as shown by IHC and gene
expression of articular cartilage speciﬁc Collagen II. Following 21
days implantation, the regenerate tissue not only showed good
integration with the host tissue but also a hyaline cartilage-like
morphology and excellent values when scored using a modiﬁed
system based on scoring systems devised by Wakitani and Ho-
raf for markers of healthy cartilage. In comparison, empty defects
showed poor repair with a ﬁbrocartilaginous tissue ﬁlling the defect
area. The presence of CM-Dil labeled cells within the defect area
demonstrated the persistence of donor cells.
Conclusions: This study points to the future use of hESC-derived
chondrogenic cells in the treatment of cartilage defects in man.
The ultimate aim of our work is to address the huge disease burden
associated with osteoarthritis and future studies will focus on ways
to support the chondrogenic cells in the harsh OA environment.
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Purpose: Articular cartilage shows poor intrinsic repair, leading
to progressive joint damage. Therapies like marrow stimulation or
tissue engineering depend on chondrogenesis of progenitor cells.
However, chondrogenesis needs to take place in a joint with a
distorted environment. We have shown that factors produced by
osteoarthritic (OA) synovium inhibit chondrogenesis of progenitor
cells. To elucidate which pathways are responsible for this inhibition
microarray analysis was performed on chondrogenic progenitor
cells treated with OA synovium- derived conditioned medium.
Methods: Human mesenchymal stem cells (hMSC) were chon-
drogenically differentiated. Cells were pelleted in serum free chon-
